疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2561人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1721194, encodeId=3a091e2119436, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L, objectType=article, longId=726654, objectId=865fe2665466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=865fe2665466, replyNumber=0, likeNumber=76, createdTime=2022-07-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=865fe2665466, moduleTitle=Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=865fe2665466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721170, encodeId=7ca51e21170f1, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=BMC Cancer：双周SOX方案一线治疗中国老年晚期或转移性G/GEJ(胃或胃食管交界处癌)的疗效和安全性, objectType=article, longId=300556, objectId=17eb300556a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17eb300556a6, replyNumber=0, likeNumber=69, createdTime=2022-09-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17eb300556a6, moduleTitle=BMC Cancer：双周SOX方案一线治疗中国老年晚期或转移性G/GEJ(胃或胃食管交界处癌)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17eb300556a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721156, encodeId=4d3d1e2115696, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性, objectType=article, longId=293700, objectId=baae293e00d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baae293e00d8, replyNumber=0, likeNumber=59, createdTime=2022-01-27, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baae293e00d8, moduleTitle=BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baae293e00d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721137, encodeId=f49e1e21137f0, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, objectType=article, longId=221412, objectId=45d222141221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d222141221, replyNumber=0, likeNumber=93, createdTime=2022-04-07, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d222141221, moduleTitle=J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d222141221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721167, encodeId=2c421e2116769, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, objectType=article, longId=299733, objectId=15e0299e3314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e0299e3314, replyNumber=0, likeNumber=78, createdTime=2022-12-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e0299e3314, moduleTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15e0299e3314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721210, encodeId=82551e212107b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=NEJM Evid：奥替康唑治疗复发性外阴阴道念珠菌病的疗效和安全性（CL-011和CL-012试验）, objectType=article, longId=734183, objectId=9cfbe3418370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cfbe3418370, replyNumber=0, likeNumber=75, createdTime=2023-07-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cfbe3418370, moduleTitle=NEJM Evid：奥替康唑治疗复发性外阴阴道念珠菌病的疗效和安全性（CL-011和CL-012试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cfbe3418370)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721070, encodeId=c5f01e210704f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JAAD:Ixekizumab 的长期疗效和安全性, objectType=article, longId=216744, objectId=ea16216e443b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea16216e443b, replyNumber=0, likeNumber=77, createdTime=2021-12-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea16216e443b, moduleTitle=JAAD:Ixekizumab 的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea16216e443b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721080, encodeId=59561e2108063, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性, objectType=article, longId=217605, objectId=134f21e60540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134f21e60540, replyNumber=0, likeNumber=92, createdTime=2022-02-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134f21e60540, moduleTitle=J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134f21e60540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721204, encodeId=03881e212046b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性, objectType=article, longId=729827, objectId=8d36e298275b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d36e298275b, replyNumber=0, likeNumber=70, createdTime=2022-08-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d36e298275b, moduleTitle=Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d36e298275b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721133, encodeId=31111e2113399, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, objectType=article, longId=221323, objectId=976a22132323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=976a22132323, replyNumber=0, likeNumber=76, createdTime=2021-11-30, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=976a22132323, moduleTitle=Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=976a22132323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721148, encodeId=75a31e2114817, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=BMC Cancer：转移性乳腺癌伴有内脏转移使用白蛋白紫杉醇的疗效和安全性, objectType=article, longId=291960, objectId=d5d029196010, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5d029196010, replyNumber=0, likeNumber=69, createdTime=2022-07-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5d029196010, moduleTitle=BMC Cancer：转移性乳腺癌伴有内脏转移使用白蛋白紫杉醇的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5d029196010)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721105, encodeId=bf7a1e2110587, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=59, createdTime=2022-10-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721118, encodeId=b8b21e211186a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：英夫利昔单抗((infliximab)和维多珠单抗(vedolizumab)) 治疗免疫介导的腹泻和结肠炎(IMDC)的疗效和安全性, objectType=article, longId=220663, objectId=82c1220663af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82c1220663af, replyNumber=0, likeNumber=69, createdTime=2022-08-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c1220663af, moduleTitle=J Immunother Cancer：英夫利昔单抗((infliximab)和维多珠单抗(vedolizumab)) 治疗免疫介导的腹泻和结肠炎(IMDC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c1220663af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721165, encodeId=718a1e21165d8, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性, objectType=article, longId=299288, objectId=c2b8299288cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b8299288cb, replyNumber=0, likeNumber=74, createdTime=2022-04-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b8299288cb, moduleTitle=J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2b8299288cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721090, encodeId=58d81e21090c4, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer：临床实践中黑素瘤的辅助治疗的疗效和安全性：临床研究与现实, objectType=article, longId=218801, objectId=83d72188016f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83d72188016f, replyNumber=0, likeNumber=80, createdTime=2022-07-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83d72188016f, moduleTitle=Eur J Cancer：临床实践中黑素瘤的辅助治疗的疗效和安全性：临床研究与现实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83d72188016f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721109, encodeId=1ffc1e2110996, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Diabetes Obes Metab：利拉鲁肽治疗1型糖尿病的疗效和安全性, objectType=article, longId=220271, objectId=d79b2202e1a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d79b2202e1a6, replyNumber=0, likeNumber=69, createdTime=2022-08-30, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d79b2202e1a6, moduleTitle=Diabetes Obes Metab：利拉鲁肽治疗1型糖尿病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d79b2202e1a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721117, encodeId=0df91e21117d9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Am J Rhinol Allergy：皮下免疫疗法治疗局部过敏性鼻炎的疗效和安全性分析, objectType=article, longId=220641, objectId=989f2206416a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989f2206416a, replyNumber=0, likeNumber=91, createdTime=2022-06-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989f2206416a, moduleTitle=Am J Rhinol Allergy：皮下免疫疗法治疗局部过敏性鼻炎的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989f2206416a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721127, encodeId=b0651e21127f4, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, objectType=article, longId=221184, objectId=7716221184e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7716221184e3, replyNumber=0, likeNumber=59, createdTime=2022-03-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7716221184e3, moduleTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7716221184e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721174, encodeId=cca91e2117428, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：利桑珠单抗治疗活动性银屑病关节炎的疗效和安全性：3期KEEPsAKE 2试验的24周结果, objectType=article, longId=301767, objectId=e074301e677e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e074301e677e, replyNumber=0, likeNumber=69, createdTime=2022-08-31, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e074301e677e, moduleTitle=Arthritis Rheumatol：利桑珠单抗治疗活动性银屑病关节炎的疗效和安全性：3期KEEPsAKE 2试验的24周结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e074301e677e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721186, encodeId=9f101e2118666, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, objectType=article, longId=724945, objectId=a43ee2494583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a43ee2494583, replyNumber=0, likeNumber=63, createdTime=2022-08-07, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a43ee2494583, moduleTitle=Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a43ee2494583)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L

2022-07-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

BMC Cancer：双周SOX方案一线治疗中国老年晚期或转移性G/GEJ(胃或胃食管交界处癌)的疗效和安全性

2022-09-18

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

BMC Cancer：曲妥珠单抗和氟维司群联合治疗HR+/HER2+转移性乳腺癌患者的疗效和安全性

2022-01-27

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：Poziotinib治疗既往经治的晚期或转移性NSCLC患者的疗效和安全性

2022-04-07

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性

2022-12-15

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

NEJM Evid：奥替康唑治疗复发性外阴阴道念珠菌病的疗效和安全性（CL-011和CL-012试验）

2023-07-01

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JAAD:Ixekizumab 的长期疗效和安全性

2021-12-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：波齐替尼(Poziotinib)治疗HER2外显子20突变的晚期NSCLC的疗效和安全性

2022-02-17

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol：派姆单抗治疗多种MSI-H/dMMR实体肿瘤的疗效和安全性

2022-08-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Oncologist: FOLFOX方案联合dasatinib（达沙替尼）一线治疗转移性胰腺癌患者的疗效和安全性

2021-11-30

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

BMC Cancer：转移性乳腺癌伴有内脏转移使用白蛋白紫杉醇的疗效和安全性

2022-07-06

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2022-10-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：英夫利昔单抗((infliximab)和维多珠单抗(vedolizumab)) 治疗免疫介导的腹泻和结肠炎(IMDC)的疗效和安全性

2022-08-18

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性

2022-04-11

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer：临床实践中黑素瘤的辅助治疗的疗效和安全性：临床研究与现实

2022-07-14

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Diabetes Obes Metab：利拉鲁肽治疗1型糖尿病的疗效和安全性

2022-08-30

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Am J Rhinol Allergy：皮下免疫疗法治疗局部过敏性鼻炎的疗效和安全性分析

2022-06-14

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究

2022-03-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arthritis Rheumatol：利桑珠单抗治疗活动性银屑病关节炎的疗效和安全性：3期KEEPsAKE 2试验的24周结果

2022-08-31

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Leukemia：Guadecitabine在外周T细胞淋巴瘤患者中的疗效和安全性

2022-08-07

科室
- - 订阅+
  - 更多科室
工具
服务